SAGA Diagnostics
Lund
About SAGA Diagnostics
SAGA Diagnostics AB is a personalized cancer diagnostics and disease monitoring company focused on molecular genetic analyses of a powerful cancer biomarker: circulating tumor DNA (ctDNA). The company was founded in 2016 as a spin-out from a highly successful research group at Lund University, with a mission to improve precision cancer medicine, provide more accurate treatment monitoring, and improve patient survival using minimally-invasive liquid biopsy cancer testing services and kits. The SAGA team consists of renowned scientists, highly qualified staff and an experienced management team who work together to launch SAGA’s ultrasensitive services and products as part of the ongoing revolution in cancer research, drug development, and clinical diagnostics. SAGA’s proprietary tests can help patients, oncologists, and drug developers detect actionable mutations, stratify patient groups, and monitor treatment response, residual disease, and disease recurrence at an unprecedented sensitivity.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $18.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jun 2021)
- Website: sagadiagnostics.com
- Phone: +46 (0)733 01 7242
Industries & Categories
Biotechnology, Genetics, Medical, Oncology
Social Profiles
Canonical: https://fsome.com/organization/saga-diagnostics-47613 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.